Array Celebrates BEACON Of Hope For Anti-BRAF/MEK/EGFR Triplet In Colorectal Cancer
New data on Array BioPharma's encorafenib and binimetinib together with cetuximab add hopes for its future in colorectal cancer. Recent strong data in melanoma for the BRAF/MEK combo are expected to be followed by its first US approval in the coming days.
You may also be interested in...
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
Having just got the nod for the combination of Braftovi and Mektovi, the French company believes the strength of its overall survival data will see the therapy successfully compete with other BRAF/MEK combos and immunotherapies for melanoma.
The latest drug development news and highlights from our US FDA Performance Tracker.